Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01733004
Title A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merrimack Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Everolimus + MM-141

MM-141

Gemcitabine + MM-141 + Nab-paclitaxel

Age Groups: adult
Covered Countries USA | FRA


No variant requirements are available.